Your session is about to expire
← Back to Search
Whole-Brain Radiation Therapy for Small Cell Lung Cancer
Study Summary
This trial is studying whether whole-brain radiation therapy is more effective with or without hippocampal avoidance in treating patients with small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 3 trial • 637 Patients • NCT00884741Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You cannot have a magnetic resonance imaging (MRI) scan if you have metal implants or severe claustrophobia.I finished my chemotherapy between 1 to 8 weeks ago.I have extensive-stage small cell lung cancer and may get chest radiation after chemotherapy.My small cell lung cancer is classified as either limited or extensive stage.I have had radiotherapy to my head or neck, excluding T1 glottic cancer, with overlapping radiation fields.I am a woman who can have children and I had a negative pregnancy test within the last 2 weeks.I will receive chemotherapy or cancer drugs during my brain radiation.I have not had any cancer other than non-melanoma skin cancer in the last 5 years.I am HIV positive with a CD4 count below 200.I can take care of myself and am up more than 50% of my waking hours.My cancer responded to chemotherapy in the last 56 days.I have completed specific brain function tests recently.Participants must have a memory test score higher than 2 at the beginning of the study.I am currently taking or allowed to take atezolizumab.I am not pregnant, breastfeeding, and if capable of childbearing or fathering children, I agree to use contraception.My cancer is a high-grade neuroendocrine or mixed small/large cell type.My last imaging after chemotherapy was within the last 56 days.You have a serious ongoing health condition.My small cell lung cancer was confirmed by a test within the last 250 days.You have signs of cancer spreading to the brain or spinal cord.There are unusual changes in the ventricles of your brain when seen on a scan.You need to have a special MRI scan with contrast dye within 56 days before joining the study.I speak English or French as my primary language.
- Group 1: Arm I (PCI using 3DCRT)
- Group 2: Arm II (PCI with HA using IMRT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What goals has this experiment been designed to meet?
"The purpose of this trial is to measure the intracranial relapse rate over a 6-month period. Secondary outcomes include patient-reported quality of life, as measured by the EORTC QLQ-C30 and BN20, cognitive function decline at 3, 6, 12, 18 and 24 months, and time to neurocognitive failure."
Is this clinical trial taking place in several locations throughout Canada?
"To name a few of the 100 other locations, this trial is enrolling patients at Christiana Care Health System-Concord Health Center in Chadds Ford, Pennsylvania, Norris Cotton Cancer Center-North in Saint Johnsbury, Vermont, and University Health Network-Princess Margaret Hospital in Toronto, Ontario."
Is this research still enrolling participants?
"This research is not recruiting patients at the moment, however according to clinicaltrials.gov this study was last updated on 11/1/2022. It's possible that patient recruitment will open up again in the future. There are 3,959 other ongoing trials that are currently looking for patients."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger